OAB and Incontinence

“The notable feature was that the bleeding risk is very small. In our particular group, it was less than 1%,” says Jai Seth, MD.

“In terms of patients having Botox, we have to be individualized to some extent where if you feel someone's at very high risk of bleeding…then maybe you will stop the blood thinners,” says Jai Seth, MD.

“Botox to [the] bladder has, in some ways, changed the paradigm of treatment for [overactive bladder],” says Jai Seth, MD.

"By all means, educate patients about causes of nocturia, suggest behavior modifications...but don’t throw a drug at them unless there are daytime symptoms of urgency, high postvoid residual, or large volume output at night," writes Gopal H. Badlani, MD.

Twenty-six percent of patients with overactive bladder reported continence at 12 months.

The pivotal OASIS trial is examining the capability of the RENOVA iStim tibial neuromodulation system to reduce urinary urgency incontinence episodes in women.

A crude logistic regression analysis showed that adjunctive pharmacotherapy did not significantly change the odds of improving nocturia severity.

The national health insurance program is now covering Elitone, a surface-applied electrical muscle stimulation device for female stress urinary incontinence that patients self-administer at home.

Amplitude setting as low as 50% below sensory level is effective for treating overactive bladder.

The device can now be marketed throughout the EU, as well as in Iceland, Liechtenstein, and Norway.

The study also showed that sexual function was comparable for women with SUI who received single incision sling versus those who underwent transobturator midurethral sling.

The implantable tibial neuromodulation device is being assessed at 8 clinical sites in the United States.

Odds of having UI were 56% higher in women with vs women without diabetes.

Vibegron (Gemtesa) is approved by the FDA for the treatment of adult patients with overactive bladder with symptoms of urge urinary incontinence.

Ninety-eight percent of the study population was female.

“The 2-year results are very impressive and underline what SNM can offer to patients with UUI," said Andrea M. Pezzella, MD.

The rechargeable implantable neurostimulator is approved for the treatment of patients with urinary and bladder dysfunction.

The updated label expands the range of MRI scan parameters and allows a briefer waiting period between MRI scans.

"We typically do urodynamics when something’s unclear and confusing. I don’t always do urodynamics before doing a sling," says 1 urologist.

Chris Du, MD, discusses findings from a study published in Neurourology and Urodynamics.

Acute urinary retention is not uncommon among men who undergo placement of a proprietary transobturator sling (AdVance) for management of postprostatectomy SUI. Still, it is rarely persistent, according to a recent study.

Investigators conducted a systematic literature review and meta-analysis assessing the impact of 3 months or longer anticholinergic use on the risk of multiple subtypes of incident dementia

“Listen. Be emphatic. Be transparent,” Pansy Uberoi, MD, MPH, advises in this interview.

The approval was based on the phase 3 EMPOWUR trial.

Experts in prostate cancer, bladder cancer, kidney stones, OAB/incontinence, BPH, and sexual dysfunction recap all the key advances from 2020.

“Some women described not being told any risks of the surgery… while other women did recall having risks described,” says investigator Pansy Uberoi, MD, MPH.

The findings support continued investigation of the safety and efficacy of mirabegron in men with OAB and concurrent ED, says study author Arthur L. Burnett, II, MD, MBA.

An application for the eCoin device has been submitted to the FDA for regulatory approval.

The FDA is considering an application for vibegron for the treatment of patients with OAB with symptoms of urge urinary incontinence, urgency, and urinary frequency.

The risk of stricture recurrence was higher with endoscopic surgery compared with urethroplasty.